News
-
-
PRESS RELEASE
Tharimmune To Participate in Two Upcoming Investor Conferences in May
Tharimmune to present at investor conferences in May 2024, showcasing developments in inflammation & immunology therapies. CEO to participate in Planet MicroCap Showcase: VEGAS 2024 & EF Hutton Annual Global Conference -
-
-
-
PRESS RELEASE
Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
Tharimmune, Inc. announces successful Phase 1 trial completion for TH104, a promising treatment for chronic pruritus in primary biliary cholangitis. The study shows positive safety and tolerability profile aligned with previous findings -
PRESS RELEASE
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
Tharimmune, Inc. completes first patient dosing in Phase 1 clinical trial for TH104, an oral thin film targeting liver-related and pruritogenic inflammatory conditions. Topline data expected in 2Q24 with full readout shortly after. Company fully funded into 2025 for Phase 1 and 2 readouts -
PRESS RELEASE
Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
Tharimmune, Inc. initiates Phase 1 trial for TH104, a buccal film with nalmefene for liver-related pruritogenic inflammatory conditions. Phase 2 planning for PBC, near-clinical pipeline and R&D day planned. Company fully funded into 2025 -
-
-
LaMar’s Donuts Celebrates National Donut Day 2024
-
abrdn U.S. Closed-End Funds Announce Distribution Payment Details
-
abrdn Income Credit Strategies Fund Announces Update and Tentative Closing Date for Acquisition of Assets From First Trust High Income Long/Short Fund
-
Electric Royalties Announces Interest Conversion Under Convertible Credit Facility
-
Pfister Faucets' American Plumber Stories Docuseries Wins Three Telly Awards
-
EQS-Adhoc: Vectron Systems AG: Vectron enters into Business Combination Agreement, resolves 10% capital increase without subscription rights of the shareholders and supports voluntary public acqusition offer
-
CPI PROPERTY GROUP publishes financial results for the first quarter of 2024
-
Leclanché SA: Publishes its Annual Report 2023 and Non-financial ESG Report
-
Spexis receives second extension for the publication of its 2023 annual report until July 31, 2024, releasing its unaudited financial statements and providing an update on its dispute with SPRIM.
-
Molten Ventures Plc: HOL-Holding(s) in Company
-
ACCOR - Description of own share buyback programme
-
ACCOR - Press release following the 2024 general meeting
-
Capital increase through exercise of subscription rights
-
NFL BIOSCIENCES: RESULTS OF THE COMBINED GENERAL MEETING OF MAY 30, 2024
-
Thales has completed the sale of its Ground Transportation Systems business